The liver in obesity and type 2 diabetes mellitus

Clinics in Liver Disease

Volumn 6, Issue 4, 2002, Pages 867-877

  Li, Zhiping ^a   Clark, Jeanne ^a   Diehl, Anna Mae ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALCOHOL; ALPHA TOCOPHEROL; BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENZYME; GAMMA GLUTAMYLTRANSFERASE; INHIBITOR KAPPA BETA KINASE; LEPTIN; LIVER ENZYME; METFORMIN; PIOGLITAZONE; PROBIOTIC AGENT; ROSAGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL OVERGROWTH; BODY MASS; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETIC OBESITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG RESEARCH; FATTY ACID OXIDATION; FATTY LIVER; FOLLOW UP; GENE MUTATION; GENETIC MANIPULATION; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; LIPID STORAGE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POPULATION RESEARCH; POSITIVE FEEDBACK; REVIEW; UNITED STATES; VIRUS INFECTION; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; OBESITY;

EID: 0036867166     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00060-0     Document Type: Review

References (78)

1. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11.
2. Harris MI, Elegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998;21:518-24.
3. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.
4. Braillon A, Capron JP, Herve MA, et al. Liver in obesity. Gut 1985;26:133-9.
5. Nomura F, Ohnishi K, Satomura Y, et al. Liver function in moderate obesity-study in 534 moderately obese subjects among 4613 male company employees. Int J Obes 1986;10:349-54.
6. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
7. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
8. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
9. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-9.
10. Volta U, De Franceshi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasemia. Lancet 1998;352:26-9.
11. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-9.
12. Yano E, Tagawa K, Yamaoka K, et al. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001;54:945-51.
13. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
14. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: The Dyonisos study. Hepatology 1994;20:1442-9.
15. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 1999;116:1413-9.
16. Teli M, James OF, Burt AD, et al. A natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-7.
17. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:342-8.
18. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1336-62.
19. Falck-Ytter Y, Younassi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
20. Bacon B, Faravash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-6.
21. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics: A clinical and histopathological comparison with alcohol-induced liver injury. Gastroenterology 1989;95:1056-60.
22. Powell EE, Cooksley GE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990;11:74-80.
23. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology 1987;7:122-8.
24. Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenerol Clin North Am 1987;16:239-52.
25. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autospy study with analysis of risk factors. Hepatology 1990;12:1106-10.
26. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-62.
27. Moitra J, Mason MM, Olive M, et al. Life without white fat: A transgenic mouse. Genes Dev 1998;12:3168-81.
28. Reitman ML, Mason MM, Moitra J, et al. Transgenic mice lacking white fat: Models for understanding human lipoatrophic diabetes. Ann N Y Acad Sci 1999;892-6.
29. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-6.
30. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREP-1c in adipose tissue: Model for congenital generalized lipodystrophy. Genes Dev 1998;12:3182-94.
31. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989;97:1022-4.
32. Campfield LA, Smith FJ, Bum P. The OB protein (leptin) pathway - A link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:619-32.
33. Friedman JM, Leibel R, Siegel DS, et al. Molecular mapping of the mouse ob mutation. Genetics 1991;11:1054-62.
34. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996;84:491-5.
35. Phillips MS, Liu Q, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 1996;13:18-9.
36. Morin-Papunen LC, Koivunen RM, Thomas C, et al. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2566-8.
37. Cohen P, Zhao C, Cai XJM, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001;108:1113-21.
38. El-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000;105:1827-32.
39. Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997;100:2900-8.
40. Lin HZ, Yang SQ, Kujhada F, et al. Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice. Nat Med 2000;6:998-1003.
41. Kern PA, Saghizaheh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
42. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin-resistance in mice lacking TNFα function. Nature 1997;389:610-4.
43. Memon RA, Hotamisligil GS, Wiesbrock SM, et al. Upregulation of uncoupling protein 2 mRNA in genetic obesity: Lack of an essential role for leptin, hyperphagia, increased tissue lipid content, and TNF-α. Biochim Biophys Acta 2000;1484:41-50.
44. Solomon SS, Mishra SK, Cwik C, et al. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-α in liver cells. Horm Metab Res 1997;29:379-82.
45. Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor α transcription in macrophages: Involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 1990;10:1498-506.
46. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001;108:437-46.
47. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 2001;293:1673-7.
48. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis. Gastroenterology 2000;119:1340-7.
49. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
50. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis: Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26:43-53.
51. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104.
52. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-11.
53. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
54. Poupon RY, Serfaty LD, Amorim M, et al. Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology 1999;30:406A.
55. Faggioni R, Fantuzzi G, Gabay C, et al. Leptin deficiency enhances sensitivity to endotoxin-induced lethality. Am J Physiol 1999;276:R136-42.
56. Honchel R, Ray RB, Marsano L, et al. Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 1992;16:665-9.
57. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-62.
58. Chavin K, Yang SQ, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274:5692-700.
59. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsy on the development of primary nonfunction after orthotopic liver transplantation. Transpl Proc 1991;23:1536-7.
60. Day CP, James O. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-5.
61. Cortez-Pinto H, Camilo ME, Baptista A, et al. Nonalcoholic fatty liver: Another feature of the metabolic syndrome? Clin Nutr 1999;18:15-9.
62. Marceau P, Iron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in servere obesity. J Clin Endocrinol Metab 1999;84:1513-7.
63. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
64. Marchesini G, Brizl M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
65. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
66. Kohlroser J, Mathai J, Reichheld J, et al. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-6.
67. Chamberlain J, DeMouy J. Diet and Exercise Dramatically Delay Type 2 Diabetes; Diabetes Medication Metformin Also Effective. Available at http:www. nih.gov/news/pr/aug2001/niddk08.html.
68. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-11.
69. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
70. Capron JP, Delamarre M, Dupas JL, et al. Fasting in obesity: Another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982;54:374-7.
71. Halverson JD, Wise L, Wazna MF, et al. Jejunoileal bypass for morbid obesity: A critical appraisal. Am J Med 1978;64:461-7.
72. Novikoff PM. Fatty liver induced in Zucker "fatty" (ff) rats by a semisynthetic diet rich in sucrose. Proc Natl Acad Sci U S A 1977;74:3550-4.
73. Poulsom R. Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol 1986;104-34.
74. Hensley K, Kotake Y, Sang H, et al. Dietary choline restrction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 2001;21:983-9.
75. Ghoshal AK, Ahluwalia M, Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol 1983;113:309-14.
76. Newbeme PM. Effect of two synthetic antioxidants, vitamin E and ascorbic acid, on the choline-deficient rat. J Nutr 1969;97:219-31.
77. Lavine JE. Vitamin E treatment of non-alcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.
78. Barak AJ, Beckenhauer HC, Badakhsh S, et al. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res 1997;21:1100-2.